A novel lonidamine derivative targeting mitochondria to eliminate cancer stem cells by blocking glutamine metabolism

A novel lonidamine derivative targeting mitochondria to eliminate cancer stem cells by blocking glutamine metabolism

Cancer stem cells (CSCs) have been blamed as the main culprit of tumor initiation, progression, metastasis, chemoresistance, and recurrence. However, few anti-CSCs agents have achieved clinical success so far. Here we report a novel derivative of lonidamine (LND), namely HYL001, which selectively an...

Full description

Bibliographic Details
Main Authors: Qiang Wang, Shiyou Li, Chen Xu, Ao Hua, Chong Wang, Yuxuan Xiong, Qingyuan Deng, Xiang Chen, Tian Yang, Jiangling Wan, Ze-yang Ding, Bi-xiang Zhang, Xiangliang Yang, Zifu Li
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:Pharmacological Research
Subjects:
HYL001
Cancer stem cells
Mitochondrial targeting
Glutamine metabolism
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661823000968

Internet

http://www.sciencedirect.com/science/article/pii/S1043661823000968

Similar Items